Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)
Obtain baseline clinical outcome data (Stage 1) upon which to base a subsequent study (Stage 2) of the Model 106 VNS implantable pulse generator
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: M106 VNS Therapy System
Eligibility
Inclusion Criteria:
- Patients with a clinical diagnosis of medically refractory epilepsy with partial onset
seizures suitable for implantation with the VNS Therapy System.
- Patients willing to undergo an EMU evaluation for a period of at least three days with
activation of the AMM feature during that time.
- Patients must be at least 12 years old.
- Patients must be in good general health and ambulatory.
- Patient or guardian must be willing and able to complete informed consent/assent.
Exclusion Criteria:
- Patients have had a bilateral or left cervical vagotomy.
- Patients currently using, or are expected to use, short-wave diathermy, microwave
diathermy, or therapeutic ultrasound diathermy.
- A VNS Therapy System implant would (in the investigator's judgment) pose an
unacceptable surgical or medical risk for the patient.
- Patients expected to require full body magnetic resonance imaging (MRI).
- Patients have a history of implantation of the VNS Therapy.
- Patients with an IQ known or estimated to be < 70, history of depression requiring
hospitalization, or suicidality as defined by DSM IV-TR that in the investigator's
judgment would pose an unacceptable risk for the patient or prevent the patient's
successful completion of the study.
- Patients with a history of status epilepticus within 1 year of study enrollment.
- Patients with known clinically meaningful cardiovascular arrhythmias as well as
patients with clinically meaningful cardiovascular arrhythmias determined by a 24-hour
Holter recording obtained during the baseline period.
- Patients dependent on alcohol or narcotic drugs as defined by DSM IV-TR within the
past 2 years.
- Patients with a history of psychogenic non-epileptic seizures.
- Women who are pregnant. Women of childbearing age must take a pregnancy test and agree
to use an approved method of contraception during the study.
- Patients currently enrolled in another investigational study.
Ages Eligible for Study
12 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Stanford Department of Neurology
(650) 498-7551
Recruiting
Psoriasis Clinical Trials
VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)
Obtain baseline clinical outcome data (Stage 1) upon which to base a subsequent study (Stage 2) of the Model 106 VNS implantable pulse generator
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: M106 VNS Therapy System
Eligibility
Inclusion Criteria:
- Patients with a clinical diagnosis of medically refractory epilepsy with partial onset
seizures suitable for implantation with the VNS Therapy System.
- Patients willing to undergo an EMU evaluation for a period of at least three days with
activation of the AMM feature during that time.
- Patients must be at least 12 years old.
- Patients must be in good general health and ambulatory.
- Patient or guardian must be willing and able to complete informed consent/assent.
Exclusion Criteria:
- Patients have had a bilateral or left cervical vagotomy.
- Patients currently using, or are expected to use, short-wave diathermy, microwave
diathermy, or therapeutic ultrasound diathermy.
- A VNS Therapy System implant would (in the investigator's judgment) pose an
unacceptable surgical or medical risk for the patient.
- Patients expected to require full body magnetic resonance imaging (MRI).
- Patients have a history of implantation of the VNS Therapy.
- Patients with an IQ known or estimated to be < 70, history of depression requiring
hospitalization, or suicidality as defined by DSM IV-TR that in the investigator's
judgment would pose an unacceptable risk for the patient or prevent the patient's
successful completion of the study.
- Patients with a history of status epilepticus within 1 year of study enrollment.
- Patients with known clinically meaningful cardiovascular arrhythmias as well as
patients with clinically meaningful cardiovascular arrhythmias determined by a 24-hour
Holter recording obtained during the baseline period.
- Patients dependent on alcohol or narcotic drugs as defined by DSM IV-TR within the
past 2 years.
- Patients with a history of psychogenic non-epileptic seizures.
- Women who are pregnant. Women of childbearing age must take a pregnancy test and agree
to use an approved method of contraception during the study.
- Patients currently enrolled in another investigational study.
Ages Eligible for Study
12 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Stanford Department of Neurology
(650) 498-7551
Recruiting
Dermatology Clinical Trials
VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)
Obtain baseline clinical outcome data (Stage 1) upon which to base a subsequent study (Stage 2) of the Model 106 VNS implantable pulse generator
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: M106 VNS Therapy System
Eligibility
Inclusion Criteria:
- Patients with a clinical diagnosis of medically refractory epilepsy with partial onset
seizures suitable for implantation with the VNS Therapy System.
- Patients willing to undergo an EMU evaluation for a period of at least three days with
activation of the AMM feature during that time.
- Patients must be at least 12 years old.
- Patients must be in good general health and ambulatory.
- Patient or guardian must be willing and able to complete informed consent/assent.
Exclusion Criteria:
- Patients have had a bilateral or left cervical vagotomy.
- Patients currently using, or are expected to use, short-wave diathermy, microwave
diathermy, or therapeutic ultrasound diathermy.
- A VNS Therapy System implant would (in the investigator's judgment) pose an
unacceptable surgical or medical risk for the patient.
- Patients expected to require full body magnetic resonance imaging (MRI).
- Patients have a history of implantation of the VNS Therapy.
- Patients with an IQ known or estimated to be < 70, history of depression requiring
hospitalization, or suicidality as defined by DSM IV-TR that in the investigator's
judgment would pose an unacceptable risk for the patient or prevent the patient's
successful completion of the study.
- Patients with a history of status epilepticus within 1 year of study enrollment.
- Patients with known clinically meaningful cardiovascular arrhythmias as well as
patients with clinically meaningful cardiovascular arrhythmias determined by a 24-hour
Holter recording obtained during the baseline period.
- Patients dependent on alcohol or narcotic drugs as defined by DSM IV-TR within the
past 2 years.
- Patients with a history of psychogenic non-epileptic seizures.
- Women who are pregnant. Women of childbearing age must take a pregnancy test and agree
to use an approved method of contraception during the study.
- Patients currently enrolled in another investigational study.
Ages Eligible for Study
12 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Stanford Department of Neurology
(650) 498-7551
Recruiting
Pediatric Dermatology Clinical Trials
VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)
Obtain baseline clinical outcome data (Stage 1) upon which to base a subsequent study (Stage 2) of the Model 106 VNS implantable pulse generator
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: M106 VNS Therapy System
Eligibility
Inclusion Criteria:
- Patients with a clinical diagnosis of medically refractory epilepsy with partial onset
seizures suitable for implantation with the VNS Therapy System.
- Patients willing to undergo an EMU evaluation for a period of at least three days with
activation of the AMM feature during that time.
- Patients must be at least 12 years old.
- Patients must be in good general health and ambulatory.
- Patient or guardian must be willing and able to complete informed consent/assent.
Exclusion Criteria:
- Patients have had a bilateral or left cervical vagotomy.
- Patients currently using, or are expected to use, short-wave diathermy, microwave
diathermy, or therapeutic ultrasound diathermy.
- A VNS Therapy System implant would (in the investigator's judgment) pose an
unacceptable surgical or medical risk for the patient.
- Patients expected to require full body magnetic resonance imaging (MRI).
- Patients have a history of implantation of the VNS Therapy.
- Patients with an IQ known or estimated to be < 70, history of depression requiring
hospitalization, or suicidality as defined by DSM IV-TR that in the investigator's
judgment would pose an unacceptable risk for the patient or prevent the patient's
successful completion of the study.
- Patients with a history of status epilepticus within 1 year of study enrollment.
- Patients with known clinically meaningful cardiovascular arrhythmias as well as
patients with clinically meaningful cardiovascular arrhythmias determined by a 24-hour
Holter recording obtained during the baseline period.
- Patients dependent on alcohol or narcotic drugs as defined by DSM IV-TR within the
past 2 years.
- Patients with a history of psychogenic non-epileptic seizures.
- Women who are pregnant. Women of childbearing age must take a pregnancy test and agree
to use an approved method of contraception during the study.
- Patients currently enrolled in another investigational study.
Ages Eligible for Study
12 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Stanford Department of Neurology
(650) 498-7551
Recruiting
VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)
Obtain baseline clinical outcome data (Stage 1) upon which to base a subsequent study (Stage 2) of the Model 106 VNS implantable pulse generator
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: M106 VNS Therapy System
Eligibility
Inclusion Criteria:
- Patients with a clinical diagnosis of medically refractory epilepsy with partial onset
seizures suitable for implantation with the VNS Therapy System.
- Patients willing to undergo an EMU evaluation for a period of at least three days with
activation of the AMM feature during that time.
- Patients must be at least 12 years old.
- Patients must be in good general health and ambulatory.
- Patient or guardian must be willing and able to complete informed consent/assent.
Exclusion Criteria:
- Patients have had a bilateral or left cervical vagotomy.
- Patients currently using, or are expected to use, short-wave diathermy, microwave
diathermy, or therapeutic ultrasound diathermy.
- A VNS Therapy System implant would (in the investigator's judgment) pose an
unacceptable surgical or medical risk for the patient.
- Patients expected to require full body magnetic resonance imaging (MRI).
- Patients have a history of implantation of the VNS Therapy.
- Patients with an IQ known or estimated to be < 70, history of depression requiring
hospitalization, or suicidality as defined by DSM IV-TR that in the investigator's
judgment would pose an unacceptable risk for the patient or prevent the patient's
successful completion of the study.
- Patients with a history of status epilepticus within 1 year of study enrollment.
- Patients with known clinically meaningful cardiovascular arrhythmias as well as
patients with clinically meaningful cardiovascular arrhythmias determined by a 24-hour
Holter recording obtained during the baseline period.
- Patients dependent on alcohol or narcotic drugs as defined by DSM IV-TR within the
past 2 years.
- Patients with a history of psychogenic non-epileptic seizures.
- Women who are pregnant. Women of childbearing age must take a pregnancy test and agree
to use an approved method of contraception during the study.
- Patients currently enrolled in another investigational study.
Ages Eligible for Study
12 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Stanford Department of Neurology
(650) 498-7551
Recruiting
VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)
Obtain baseline clinical outcome data (Stage 1) upon which to base a subsequent study (Stage 2) of the Model 106 VNS implantable pulse generator
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- device: M106 VNS Therapy System
Eligibility
Inclusion Criteria:
- Patients with a clinical diagnosis of medically refractory epilepsy with partial onset
seizures suitable for implantation with the VNS Therapy System.
- Patients willing to undergo an EMU evaluation for a period of at least three days with
activation of the AMM feature during that time.
- Patients must be at least 12 years old.
- Patients must be in good general health and ambulatory.
- Patient or guardian must be willing and able to complete informed consent/assent.
Exclusion Criteria:
- Patients have had a bilateral or left cervical vagotomy.
- Patients currently using, or are expected to use, short-wave diathermy, microwave
diathermy, or therapeutic ultrasound diathermy.
- A VNS Therapy System implant would (in the investigator's judgment) pose an
unacceptable surgical or medical risk for the patient.
- Patients expected to require full body magnetic resonance imaging (MRI).
- Patients have a history of implantation of the VNS Therapy.
- Patients with an IQ known or estimated to be < 70, history of depression requiring
hospitalization, or suicidality as defined by DSM IV-TR that in the investigator's
judgment would pose an unacceptable risk for the patient or prevent the patient's
successful completion of the study.
- Patients with a history of status epilepticus within 1 year of study enrollment.
- Patients with known clinically meaningful cardiovascular arrhythmias as well as
patients with clinically meaningful cardiovascular arrhythmias determined by a 24-hour
Holter recording obtained during the baseline period.
- Patients dependent on alcohol or narcotic drugs as defined by DSM IV-TR within the
past 2 years.
- Patients with a history of psychogenic non-epileptic seizures.
- Women who are pregnant. Women of childbearing age must take a pregnancy test and agree
to use an approved method of contraception during the study.
- Patients currently enrolled in another investigational study.
Ages Eligible for Study
12 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Stanford Department of Neurology
(650) 498-7551
Recruiting